Intranasally and orally active GH secretagogues are useful clinical tools: so why are they not on the market?
Laron
Z
Z
Endocrinology and Diabetes Research Unit, Schneider Children's Medical Center of Israel, WHO Collaborating Center for the Study of Diabetes in Youth, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. laronz@clalit.org.il
D000281:Administration, Intranasal; D000284:Administration, Oral; D000818:Animals; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D008389:Marketing of Health Services; D009842:Oligopeptides / Q000008:administration & dosage*
D009842:Oligopeptides; C086184:hexarelin; D013006:Growth Hormone